CA2828128A1 — Contrast agents for myocardial perfusion imaging
Assigned to Lantheus Medical Imaging Inc · Expires 2005-09-01 · 21y expired
What this patent protects
The invention is generally directed to contrast agents and their use for imaging myocardial perfusion. In some embodiments, the contrast agent comprises fenazaquin of a fenazaquin analog and an imaging moiety attached thereof. In some embodiments, the imaging agent comprises a fo…
USPTO Abstract
The invention is generally directed to contrast agents and their use for imaging myocardial perfusion. In some embodiments, the contrast agent comprises fenazaquin of a fenazaquin analog and an imaging moiety attached thereof. In some embodiments, the imaging agent comprises a formula such as: (see formula II), (see formula V), (see formula IV), or (see formula I).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.